AHA today submitted comments to the Department of Commerce on its Section 232 national security investigation of pharmaceutical and pharmaceutical ingredients imports. The AHA urged the administration to maintain tariff exceptions, particularly for products already experiencing shortages and for countries that produce a significant portion of the U.S. market supply of pharmaceuticals and pharmaceutical ingredients.

“The lives of patients often depend on the ready availability of drugs to respond to emergent conditions like heart attacks and infections, and other critical illnesses like cancer and organ failure. The supply chain for pharmaceutical products is highly complex and requires hospitals to draw on both domestic and international sources,” the AHA said. “For many patients, even a temporary disruption in their access to these needed medications could put them at significant risk.”

Related News Articles

Headline
President Trump, late Sept. 25, announced that starting Oct. 1, the U.S. will impose a 100% tariff on any branded or patented pharmaceutical product, unless a…
Headline
The Department of Commerce Sept. 24 released a notice seeking public comment on an investigation it launched Sept. 2 on imports of personal protective…
Headline
The Food and Drug Administration has identified a Class I recall of certain Olympus ViziShot 2 FLEX Needles due to a possible patient safety issue caused by a…
Headline
The White House Sept. 5 issued an executive order modifying the scope of reciprocal tariffs announced in April to establish a framework of trade deals with…
Headline
A JAMA study published Aug. 20 found that nearly 63% of all U.S. drug production facilities from 2019 through 2024 were in counties where a weather disaster…
Headline
B. Braun Medical has voluntarily recalled two lots of Lactated Ringer’s Injection USP 1000 mL and 0.9% Sodium Chloride Injection USP 1000 mL IV fluids due to…